Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Dextrin or derivative

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514023000 - Carbohydrate (i.e., saccharide radical containing) DOAI

514054000 - Polysaccharide

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20130045947PLA2ACTIVITY AS A MARKER FOR OVARIAN AND OTHER GYNECOLOGIC CANCERS - Materials and Methods are provided for the diagnosis, monitoring, and personalized treatments of gynecological cancers. The methods comprise determining levels of PLA02-21-2013
20130029937TREATMENT OF SURFACTANTS - The invention relates to a method for enhancing a surfactant, in particular a pulmonary surfactant, as well as a method for producing a surfactant enhancement agent, in particular a pulmonary surfactant enhancement agent. The invention also relates to a surfactant enhancement agent and a use of an enhancement agent for enhancing a surfactant, in particular, a pulmonary surfactant. Further, the invention relates to a method of mitigating oxidative damage to pulmonary surfactant by adding a cholesterol-sequestrating agent such as cyclodextrin. Finally, a method is provided for treating a patient having surfactant dysfunction due to oxidative damage to pulmonary surfactant by administering a surfactant-protective amount of a cholesterol-sequestrating agent to protect the surfactant from the negative effects of oxidative degradation. In the examples we show that MβCD, a cholesterol-sequestrating agent, can restore dysfunctional surfactant removed from the lungs of children with cystic fibrosis and non CF bronchiolitis to normal function.01-31-2013
20130029936Inclusion Compounds of Fumagillol Derivative or its Salt, and Pharmaceutical Compositions Comprising the Same - The present invention relates to an inclusion compound of fumagillol derivative or its salt with hydroxypropyl-β-cyclodextrin or sulfobutylether-7-β-cyclodextrin, and pharmaceutical compositions comprising the same. The inclusion compound according to the present invention has superior water solubility and stability while exhibiting low toxicity, rendering it valuable as an anticancer agent or inhibitor of tumor metastasis.01-31-2013
20100075923METHOD OF ENHANCING TGF-BETA SIGNALLING - The present invention is directed to a method of enhancing TGF-β signaling in a subject comprising administering to said subject a clathrin-dependent endocytosis inhibitor in an amount sufficient to enhance TGF-β signaling. In another aspect, the invention is directed to a method of treating a condition associated with decreased TGF-β signaling in a patient in need thereof comprising administering to said patient a clathrin-dependent endocytosis inhibitor in a therapeutically effective amount.03-25-2010
20090270348Sulfoalkyl Ether Cyclodextrin Compositions - SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD composition comprises a sulfoalkyl ether cyclodextrin and less than 100 ppm of a phosphate, wherein the SAE-CD composition has an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.10-29-2009
201001133888-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT - An 8-azaprostaglandin represented by formula (I)05-06-2010
20100113387FATTY ACIDS FOR USE AS A MEDICAMENT - The invention relates to fatty acid stimulation of rectal mucosa initiating the process of defecation, acting as a laxative. Furthermore, the invention relates to the usage of free fatty acids, fatty acid mixtures and fatty acid extracts from marine lipids in pharmaceutical formulations such as suppositories, ointments, tablets and gelatin capsules for treatment and prevention of multiple disorders like constipation, hemorrhoids, bacterial infections (e.g. 05-06-2010
20100099647Aqueous Iron Carbohydrate Complexes, Their Production And Medicaments Containing Them - Water soluble iron carbohydrate complex obtainable from an aqueous solution of iron(III) salt and an aqueous solution of the oxidation product of one or more maltodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, process for its production and medicament for the treatment and prophylaxis of iron deficiency conditions.04-22-2010
20100144670Particle Formation - A process for producing particles of a substance is described wherein a solution of the substance in a solvent is delivered in at least one shot into a supercritical fluid. The supercritical fluid is a non-solvent for the substance and is miscible with the solvent. Particles of the substance distributed in a mixture of the solvent and the supercritical fluid are formed.06-10-2010
20100041625PHARMACEUTICAL COMPOSITION COMPRISING CYCLODEXTRIN PACLITAXEL INCLUSION AND PREPARATION METHOD THEREOF - A pharmaceutical composition comprising cyclodextrin/paclitaxel inclusion, which consists of paclitaxel, cyclodextrin and a pharmaceutically acceptable excipient, wherein the mass ratio of the paclitaxel to cyclodextrin is 1:10-150, the said cyclodextrin is hydroxylpropyl-sulfobutyl-7-β-cyclodextrin, or sulfobutylether-7-β-cyclodextrin, or their mixture; the stability constant of the cyclodextrin/paclitaxel inclusion is Ka=5396M−1−1412M−1. The preparation method of the pharmaceutical composition is as follow: (a) A solution of cyclodextrin is added dropwise to a solution of paclitaxel in ethanol. (b) The resulting mixture is filtered through microporous membrane of 0.2-0.4 μm after being dissolved. (c) Ethanol is removed under reduced pressure to give a liquid inclusion which has the ethanol level of less than 2%, or alternatively water is also removed under reduced pressure, the resulting product is dried giving a solid inclusion.02-18-2010
20100022474Polymer Controlled Induced Viscosity Fiber System and Uses Thereof - The present invention relates generally to a method of blunting the postprandial glycemic response in a human by feeding an induced viscosity fiber system. The invention also relates to an induced viscosity fiber system and the liquid products that incorporate the induced viscosity fiber system. Further, the invention relates to a method of incorporating soluble fiber into a liquid product without the typical negative organoleptic or physical stability issues. The invention also relates to a method of inducing the feeling of fullness and satiety by feeding the induced viscosity fiber system.01-28-2010
20130059817COMPOSITION FOR REDUCING ABSORPTION OF DIETARY FAT - This invention relates to compositions for reducing the absorption or bioavailability of lipids in the gastrointestinal tract, and to methods for the preparation and use of these compositions. The compositions comprise a source of dietary fibre together with a cyclodextrin. The compositions of the invention are suitable for use in the prevention and treatment of obesity or hyperlipidaemia.03-07-2013
20130059816COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE - Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.03-07-2013
20090270349Physical Mode of Action Pesticide - A physical mode of action pesticide for application on plants and in soils, and methods of manufacture and application, comprising an active ingredient in the form of a polymer in a concentration of less than 0.1% wt., a surfactant, a co-solvent and a diluent in a hydrocolloid suspension. The suspension polymer is preferably a polysaccharide having a molecular weight of 10,000 to 25,000,000, and preferably in the range of about 600,000. The pesticide preferably also includes a targeting ingredient for directing the active ingredient to a particular target.10-29-2009
20110021458PHARMACEUTICAL COMPOSITIONS CONTAINING AN INCLUSION COMPLEX FORMED BY DISULFIRAM AND A CYCLODEXTRINE, WHICH CAN BE USED IN THE TREATMENT OF ALCOHOL AND COCAINE DEPENDENCE - The invention relates to a novel pharmaceutical composition containing a complex of disulfiram (DSF) with a cyclodextrin (CD), to the method for obtaining same and to the use thereof in the treatment of alcohol and cocaine dependence.01-27-2011
20090012042Hydroxypropyl-Sulfobutyl-Beta-Cyclodextrin, the Preparation Method, the Analytical Method, and the Pharmacutical Application Thereof - Hydroxypropyl-sulfobutyl-&bgr;-cyclodextrin, the preparation method, analytical method, and the pharmaceutical application thereof. The hydroxypropyl-sulfobutyl-&bgr;-cyclodextrin is a derivate of cyclodextrin which is substituted by hydroxypropyl group and sulfobutyl group: n-(2,3,6-O-2-hydroxypropyl)-m-(2,3,6-O-sulfobutyl)-&bgr;-cyclodextrin. The number of substituent groups per mole cyclodextrin is n hydroxypropyl groups and m sulfobutyl groups. “n” represents the average substituent degree of hydroxypropyl groups; “m” represents the average substituent degree of sulfobutyl groups; “n+m=z” is the gross average substituent degree, in which n is a random integer chosen from 1, 2, 3, 4, 5, 6, 7, 8, 9; m is a random integer chosen from 1, 2, 3, 4, 5, 6, 7, 8, 9; and the gross average substituent degree z is a random integer chosen from 2, 3, 4, 5, 6, 7, 8, 9, 10. The present invention shows low haemolysis and low toxicity.01-08-2009
20120238525PERITONEAL DIALYSIS SOLUTIONS COMPRISING GLUCOSE POLYMERS - Peritoneal dialysis solutions including a glucose polymer and methods of using the dialysis solutions are disclosed herein. In a general embodiment, the peritoneal dialysis solution includes a glucose polymer in an amount to provide an increased ultrafiltration fluid volume for a given amount of carbohydrate absorbed compared to conventional dialysis solutions containing icodextrin as the active pharmaceutical ingredient. The increased ultrafiltration fluid volume for a given amount of carbohydrate absorbed is obtained by providing specific combinations of weight-average molecular weight, polydispersity index and concentration of the glucose polymer in the dialysis solution.09-20-2012
20130165405CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY - The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.06-27-2013
20090291913FACTOR Xa INHIBITOR FORMULATION AND METHOD - An injectable Factor Xa inhibitor formulation is provided which includes the Factor Xa inhibitor razaxaban or apixaban, a solubilizing agent which is a substituted β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin (SBE-CD) or hydroxypropyl-β-cyclodextrin (HPB-CD), and water. A method for preventing or treating venous thrombosis, deep venous thrombosis and acute coronary syndrome employing the above formulation is also provided.11-26-2009
20110144053Process for Obtaining Purified Pterostilbene and Methods of Use Thereof - The present invention relates to a process of extraction and purification of a stilbenoid, pterostilbene, from botanical sources. The process involves obtaining pterostilbene having high degree of purity and the present invention also relates to pure form of pterostilbene obtained. The invention also relates to complexing the pterostilbene with carriers such as cyclodextrin for improving its water solubility and bioavailability. The present invention also describes a process for inhibition of Histone Deacetylases using pterostilbene optionally along with a carrier, and a method of managing Poly Glutamine repeat disorders by the administration of pterostilbene optionally along with a carrier.06-16-2011
20090023682Composition Comprising Dietary Fat Complexer and Methods of Using Same - A composition includes α-cyclodextrin and at least one lipase inhibitor. A method for promoting weight loss, inhibiting weight gain, or maintaining weight in a subject in need thereof includes administering α-cyclodextrin and at least one lipase inhibitor to the subject, thereby reducing the bioavailability of ingested fat and reducing the unpleasant gastrointestinal side effects.01-22-2009
20080269167Preparation Comprising Iron(III) Complex Compounds And Redox-Active Substance(s) - A preparation is disclosed that comprises one or more iron(III) complex compounds which have a redox potential at pH 7 of from −324 mV to −750 mV relative to a normal hydrogen electrode (NHE), and one or more redox-active substances, wherein the carbohydrates are selected from the group consisting of dextrans and hydrogenated dextrans, dextrins, oxidised or hydrogenated dextrins, as well as pullulan, oligomers thereof and/or hydrogenated pullulans, and wherein the redox-active substance(s) is/are selected from the group consisting of ascorbic acid; vitamin E; cysteine; physiologically acceptable phenols/polyphenols selected from the group consisting of quercetin, rutin, flavones, flavonoids, hydroquinones; and glutathione, and in particular is ascorbic acid.10-30-2008
20110288049Compositions, Systems, and/or Methods Involving Chlorine Dioxide ("ClO2") - Certain exemplary embodiments can provide a composition of matter comprising a solid form of chlorine dioxide complexed with a cyclodextrin. The concentration of chlorine dioxide in said solid form is greater than approximately 5.8 percent by weight. Certain exemplary embodiments can provide a method comprising forming a solid complex comprising chlorine dioxide and cyclodextrin, wherein a concentration of chlorine dioxide in the solid complex is greater than 5.8 percent by weight.11-24-2011
20110172182Carboxyethylated Cyclodextrin Polysulfates Useful As Medicaments - This invention relates to novel β-cyclodextrin polysulfate compounds comprising from one to three 2-carboxyethyl substituents, and at least two sulfates groups per glucopyranose unit, which are useful as active ingredients for the treatment and/or prophylaxis of degenerative joint diseases, osteoarthritis, articular rheumatism, arthrosis or degenerative arthritis, or for the treatment of heparin-induced thrombocytopenia, or for cartilage repair or connective tissue repair.07-14-2011
20090012041Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases - The invention provides the use of a cyclodextrin compound for the manufacturing of a medicament for the treatment or prevention of bronchial inflammatory diseases, particularly for asthma.01-08-2009
20100204179Resveratrol complex and process for the preperation - The present invention provides products having resveratrol with high water solubility and nutraceutical and/or phytotherapic compositions having said substances. The processes for obtaining them include the solubility increase of the polyphenol corresponding to a resveratrol compound, preferably trans-resveratrol in water, by its complexation with cyclodextrin under specific conditions that favor thermodynamic equilibrium. The products of the invention present high solubility and purity in aqueous medium, being, therefore, useful to prepare nutraceutical compositions (pharmaceutical and/or alimentary) with antioxidant, anti-inflammatory, antiviral, antidiabetics, cardioprotective, neuroprotective, chemoprotective activities; besides protecting against infections and ischemia, reducing obesity, and preventing aging. Phytotherapic compositions useful to the same therapeutical activities, prepared from the complex of resveratrol and cyclodextrin compound, preferably beta-cyclodextrin/trans-resveratrol, are also provided.08-12-2010
20100298265Inclusion complex of raloxifene hydrochloride and beta-cyclodextrin - There is described an inclusion complex of raloxifene hydrochloride and β-cyclodextrin in the solid phase having a specific X-ray powder diffraction spectrum. The invention also relates to a process for obtaining the raloxifene hydrochloride inclusion complex with β-cyclodextrin of the invention. The complex of the invention is employed as a pharmaceutical ingredient in the treatment of osteoporosis, specifically postmenopausal osteoporosis.11-25-2010
20120065161CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY - Methods and compositions relating to CDP-epothilone conjugates are described herein.03-15-2012
20120295872Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases - The invention provides the use of a cyclodextrin compound for the manufacturing of a medicament for the treatment or prevention of bronchial inflammatory diseases, particularly for asthma.11-22-2012
20090275530Gastric Raft Composition Comprising Preferably Processed Starches For Inducing Satiety - Provided are methods of inducing satiety in an individual using gastric raft compositions and compositions suitable for such methods. The gastric raft compositions may comprise processed starches such as dextrins. Also described are methods of treating diseases characterised by hypoglycaemia, such as glycogen storage disease (GSD), and diabetes.11-05-2009
20090286757Antiviral composition - Chemical compounds, being the alkyl sulfate of sulfated saccharides, particularly, dextrin, dextran, and cyclodextrin, and pharmaceutical compositions containing these compounds. The compounds of the invention provide antiviral activity, particularly in the treatment and prevention of sexually-transmitted diseases. Methods of treating viral infection and preventing viral transmission include administration include administration of the compounds of the invention orally, topically, subcutaneously, by muscular injection, by intraperitoneal injection and by intravenous injection.11-19-2009
20110207697XANTHOHUMOL COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES OR DISORDERS - The present invention features therapeutic and prophylactic compositions comprising xanthohumol and/or xanthohumol/cyclodextrin complexes and methods of using such compositions for treating a skin condition, disease, or disorder.08-25-2011
20120035130Chirally Correct Retinal Cyclodextrin Acetals for Clarifying Skin Complexion - The present invention discloses certain chirally correct polyene cyclodextrin acetals and hemiacetals (formula I) that are effective in providing skin clarification, which is useful for the treatment of acne, and skin disfigurements and skin darkening resulting from acne; skin darkening from cancer, diabetes, radiation treatments, chemotherapy, and sun-burn; mitochondrial and DNA dysfunction; age spots; loss of cellular antioxidants; skin changes associated with aging including collagen loss, loss of skin pliability, loss of skin suppleness, skin wrinkles and fine lines, oxidation, damage from radiation, damage from free radicals, and damage from UV; dry skin; xerosis; ichthyosis; dandruff; brownish spots; keratoses; melasma; lentigines; liver spots; skin pigmentation including pigmented spots, dark circles under the eyes, darkened skin, and blemishes; oily skin; warts; eczema; pruritic skin; psoriasis; inflammatory dermatoses; topical inflammation; disturbed keratinization; scalp dryness, and combinations thereof;02-09-2012
20090054375Compositions, Systems, and/or Methods Involving Chlorine Dioxide - Certain exemplary embodiments can provide a composition of matter comprising a solid form of chlorine dioxide complexed with a cyclodextrin. When stored, a concentration of the chlorine dioxide in the composition of matter can be retained, with respect to an initial concentration of chlorine dioxide in said composition of matter, at, for example, greater than 12% for at least 14 days. Certain exemplary embodiments can provide a method comprising releasing chlorine dioxide from a solid composition comprising chlorine dioxide complexed with a cyclodextrin.02-26-2009
20080261916Synergistic Prebiotic Compositions - The invention relates to synergistic compositions comprising prebiotic components selected from fructose polymers GF10-23-2008
20090239823FOODS AND DRINKS HAVING HEALTH BENEFITS AND METHOD FOR ADDING HEALTH BENEFITS TO FOODS AND DRINKS - A method for controlling intestinal function, blood sugar level, body fat or serum lipid, or maintaining and improving glucose tolerance. The method comprises giving to human body or animal foods and drinks, having health benefits, or enriched with health benefits, wherein the foods and drinks comprise as an active ingredient a hydrogenated, indigestible dextrin that is obtained by digesting pyrodextrin with an enzyme to obtain an indigestible dextrin, and then hydrogenating the indigestible dextrin.09-24-2009
20100152134EMULSIFIED SKIN EXTERNAL PREPARATION AND METHOD FOR STABILIZING THE SKIN EXTERNAL PREPARATION - An emulsified skin external preparation containing a tocopherol glycinate derivative has excellent storage stability without viscosity reduction during storage. The emulsified skin external preparation includes 0.03 to 25% by mass of a tocopherol glycinate derivative, and 0.05 to 25% by mass of at least one fatty acid ester selected from the group consisting of glycerin mono fatty acid ester, polyglycerin fatty acid ester and dextrin fatty acid ester, the tocopherol glycinate derivative being represented by Formula (1): . . . (1) wherein R06-17-2010
20100093662NOVEL AMPHIPHILIC CYCLODEXTRIN DERIVATIVES - The present invention relates to cyclodextrins having the following formula (I): to nanostructures comprising them, to processes for preparing them, to the use thereof, and also to compositions comprising them.04-15-2010
20100184722INCLUSION COMPLEXES OF ALPHA-CYCLODEXTRIN AND SILDENAFIL SALT - Provided are inclusion complexes comprising a sildenafil salt (e.g., sildenafil citrate) and alpha-cyclodextrin. The complexes may be useful treating various conditions, such as male erectile dysfunction and pulmonary hypertension. In some instances the inclusion complexes increase the solubility of sildenafil. Also provided are methods of producing the inclusion complexes, as well as methods of treatment, kits and unit dosages.07-22-2010
20130123214USE OF DELTA TOCOPHEROL FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS - This disclosure relates generally to the treatment of lysosomal storage disorders. Specifically, the disclosure relates to a novel use of delta tocopherol in the treatment of diseases and conditions related to lysosomal storage disorders. Included in the present disclosure is a method for the modulation of cholesterol recycling. Further, the disclosure relates to conditions such as Niemann-Pick type C disease, Farber disease, Niemann-Pick type A disease, Wolman disease and Tay Sachs disease. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of delta tocopherol. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of delta tocopherol in combination with cyclodextrin to a patient in need thereof.05-16-2013
20120196831COMPOSITION FOR TREATING AND PREVENTING OBESITY INCLUDING HIGH WATER-SOLUBLE 2-HYDROXYPROPYL-betaCYCLODEXTRIN AS EFFECTIVE COMPONENT - There is provided a composition for preventing and treating obesity including high water-soluble β-cyclodextrin derivatives as an effective component. Specifically, the composition including the high water-soluble β-cyclodextrin derivatives, especially, 2-hydroxypropyl-β-cyclodextrin (HP-β-CD, HPBCD) has effects on suppressing an increase in body weight induced by a high fat diet, suppressing appetite through decreasing an amount of dietary intake, decreasing body fat, decreasing liver weight, and significantly decreasing a sharp increase of blood sugar induced by intaking glucose and maltose on an empty stomach so that it can be useful for preventing and treating obesity, preventing and treating various diseases induced by obesity, and suppressing a sharp increase of blood sugar after dinner.08-02-2012
20100240606ASSOCIATIONS OF XANTHOGENATES AND CYCLODEXTRINS, AND THEIR USE - The invention is related to association products of xanthates and cyclodextrins, pharmaceutical formulations made therefrom, and medicaments containing these formulations for treating Alzheimer's, viral, tumor, cardiovascular, and autoimmune diseases such as rheumatism, multiple sclerosis, alopecia areata, lupus erythematosus, stroke, lung edema, or for use as radio-protectors. The association products contain a xanthate of general formula I09-23-2010
20110028431ORAL MUCOADHESIVE DOSAGE FORM - A direct compression formulation suitable for preparing buccal and/or sublingual and dosage forms incorporates a combination of a non-ionic polymeric solubility enhancer, a mucoadhesive polymer, a filler, a disintegrant, and a pharmaceutically active agent. Cannabinoid-cyclodextrin complexes exhibiting an improved property selected from improved stability, higher product yield and improved product uniformity may be obtained by complexing the cannabinoid with the cyclodextrin in a liquid medium containing an antioxidant. To enhance stability, product yield and/or product uniformity, complexing may be done while the liquid medium is in contact with an atmosphere having a very low oxygen content. The resulting complexes may be combined with decomplexing agents and/or dispersed in a matrix material comprised of a hydrogel-forming polymer to provide enhanced absorption of the cannabinoid through oral mucosa and reduced ingestion of the cannabinoid as compared with known commercially available cannabinoid-containing oral dosage forms.02-03-2011
20090111772FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY - The present invention relates to a composition comprising an inclusion complex of a cyclodextrin and quinazoline containing zinc-binding moiety based derivatives. The cyclodextrin is preferable a β-cyclodextrin or a derivative thereof. The quinazolines have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.04-30-2009
20110245201TREATMENT OF CANCER - Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.10-06-2011
20110034412VISUALLY OBSERVABLE MATERIAL FOR MEDICAL TREATMENT - A visually observable material for medical treatment, which is preferable as an adhesion preventive material and a hemostatic material for biological organisms includes a crosslinking composition comprising at least two components of a crosslinking polysaccharide derivative with an active ester group reactive with active hydrogen in the co-presence of an alkali, where the active ester group is preliminarily introduced in a side chain of a polysaccharide and the crosslinking polysaccharide derivative is not yet crosslinked, and a carbonate including at least one type of carbonate generating divalent carbonate ion in an amount at a mass ratio of 0.03 or more to the polysaccharide derivative.02-10-2011
20110086815NOVEL COMPOSITIONS CONTAINING XANTHOHUMOL-CYCLODEXTRIN COMPLEXES - The invention provides compositions comprising xanthohumol/cyclodextrin complexes that are water soluble and that have increased stability relative to xanthohumol alone.04-14-2011
20100056476PHARMACEUTICAL COMPOSITIONS COMPRISING PERANHYDROCYCLODEXTRIN - The present invention relates to a pharmaceutical composition comprising a peranhydrocyclodextrin, a drug and a carrier, to the use of a peranhydrocyclodextrin as a drug transport enhancer (e.g. permeation enhancer), and to the use of a peranhydrocyclodextrin in the preparation of a pharmaceutical composition as a synergistic adjunctive system.03-04-2010
20110082105COMPOSITIONS COMPRISING SUPERHYDROPHILIC AMPHIPHILIC COPOLYMERS AND METHODS OF USE THEREOF - Provided are compositions comprising a superhydrophilic amphiphilic copolymer and a carrier and composition comprising a superhydrophilic amphiphilic copolymer, a micellar thickener and a carrier.04-07-2011
20110251157Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid - An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.10-13-2011
20110071110Water Dispersible Policosanol Cyclodextrin Complex and Method of its Production - Disclosed is a formulation of policosanol with natural cyclodextrins resulting in a water dispersible form of policosanol. The disclosed process provides an economical commercial method for making the policosanol complex. The complex is suitable for incorporation into oral dosage forms and also in functional foods. One aspect of the present disclosure is a process for making a water dispersible policosanol cyclodextrin complex for animal ingestion. This method includes preparing a policosanol cyclodextrin complex and administering said complex to an animal. The preferred animal is a human with the route of administration being oral ingestion. The form of the complex for ingestion can be a hard gelatin capsule, tablet or wafers, which may contain other ingredients, both active and inactive. The complex also can be further formulated with excipients suitable for soft gelatin capsules, such as, for example, vegetable oils, waxes, lecithin, and surfactants such as Tween-80.03-24-2011
20110071108Beta-Cyclodextrin Derivatives as Antibacterial Agents - The invention provides a new class of antibiotics to which pathogenic bacteria have not been exposed, and thus should not have developed resistance. This new class of antibiotics are derivatives of β-cyclodextrin (β-CD), which is a cyclic molecule comprising seven D-glucose units.03-24-2011
20120202773PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT - A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP08-09-2012
20100261672PHARMACEUTICAL COMPOSITIONS OF PYRIMIDINE-2,4,6-TRIONES - A trioxopyrimidine-cyclodextrin complex formed of a trioxopyrimidine derivative or a salt thereof and a water-soluble cyclodextrin derivative has improved solubility.10-14-2010
20120202772CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY - Methods and compositions relating to CDP-proteasome inhibitor conjugates are described herein.08-09-2012
20080242636MODIFIED CYCLODEXTRIN SULFATE-71 (TERIGYN) AS A MICROBICIDE AGENT - A method of reducing human immunodeficiency virus infective events by applying terygyn and a suitable excipient formulated for topical administration to the vaginal, anal, urethral or penile glans mucosa of an individual prior to or subsequent to infection by human immunodeficiency virus is herein described.10-02-2008
20080214497Water dispersible policosanol cyclodextrin complex and method of its production - Disclosed is a formulation of policosanol with natural cyclodextrins resulting in a water dispersible form of policosanol. The disclosed process provides an economical commercial method for making the policosanol complex. The complex is suitable for incorporation into oral dosage forms and also in functional foods. One aspect of the present disclosure is a process for making a water dispersible policosanol cyclodextrin complex for animal ingestion. This method includes preparing a policosanol cyclodextrin complex and administering said complex to an animal. The preferred animal is a human with the route of administration being oral ingestion. The form of the complex for ingestion can be a hard gelatin capsule, tablet or wafers, which may contain other ingredients, both active and inactive. The complex also can be further formulated with excipients suitable for soft gelatin capsules, such as, for example, vegetable oils, waxes, lecithin, and surfactants such as Tween-80.09-04-2008
20110028432USE OF CYCLODEXTRIN FOR TREATMENT AND PREVENTION OF BRONCHIAL INFLAMMATORY DISEASES - The invention provides the use of a cyclodextrin compound for the manufacturing of a medicament for the treatment or prevention of bronchial inflammatory diseases, particularly for asthma.02-03-2011
20120077774COMPOSITIONS AND THEIR USE FOR REMOVING CHOLESTEROL - The invention is directed to compositions that function to remove cholesterol from a mammal suffering from an elevated cholesterol level. The composition includes a polysaccharide having attached thereto at least one cyclic oligosaccharide. In a particular embodiment, the foregoing composition further includes at least one cell-targeting agent. The invention is also directed to methods that utilize these compositions for removing or reducing cholesterol and other lipids in a mammal suffering from an elevated level of cholesterol and/or other lipid.03-29-2012
20110071109HISTONE DEACETYLASE INHIBITORS AS THERAPEUTIC AGENTS FOR LYSOSOMAL STORAGE DISORDERS - Embodiments herein relate to the field of lysosomal storage disorders, and, more specifically, to methods of treating lysosomal storage disorders such as Niemann-Pick type C disease, for instance with inhibitors of histone deacetylases, particularly inhibitors of class 1 histone deacetylases. In various embodiments, methods of treating Niemann-Pick type C disease with inhibitors of class 1 histone deacetylases are described.03-24-2011
20110257126WATER SOLUBLE CURCUMIN COMPOSITIONS FOR USE IN ANTI-CANCER AND ANTI-INFLAMMATORY THERAPY - The present invention relates to the medical field. In a first aspect the present invention relates to novel water soluble cyclodextrin-curcumin complexes having a pharmacological activity, in particular an anti-tumour and/or anti-inflammatory activity, and improved physico-chemical properties. In a second aspect, the present invention relates to a method for preparation of said water soluble curcumin derivatives. The invention further relates in a third aspect to a pharmaceutical composition comprising an effective amount of said water soluble curcumin derivatives. In a fourth aspect, the present invention concerns the use of said water soluble cucumin derivatives as a medicament and the use of said water soluble curcumin derivatives for the preparation of a medicament for the treatment of cancer and inflammatory diseases. In a fifth aspect, the present invention relates to the use of a pharmaceutical composition comprising said water soluble curcumin derivatives in the treatment of cancer and inflammatory diseases and to a new pharmaceutical composition comprising said water soluble curcumin derivatives.10-20-2011
20100179103CURCUMIN CYCLODEXTRIN COMBINATION FOR PREVENTING OR TREATING VARIOUS DISEASES - Curcumin has shown anti-inflammatory and anti-angiogenic properties that could be useful in treating various diseases such as those of rheumatology and oncology. However, curcumin is very poorly absorbed and has a very low bioavailability. This patent describes a method of increasing the delivery of curcumin by complexing it with cyclodextrins. Cyclodextrins are well known in the food industry and have been used to carry other drugs to increase bioavailability. The new combination of cyclodextrins and curcumin has been tested in pre-clinical inflammation models where it has demonstrated efficacy superior to both the positive control and curcumin.07-15-2010
20100168060SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF - Salts of benzimidazolyl pyridyl ethers are provided, particularly salts of {1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy]-1H-benzoimidazol-2-yl}-(4-trifluoromethyl-phenyl)amine. Compositions and formulations including such salts and surfactants as well as methods of preparing such compositions and formulations are provided.07-01-2010
20120309712Compositions Comprising Dietary Fat Complexer and Methods for Their Use - This invention relates to fat containing consumable food products comprising α-cyclodextrin. The food products have reduced levels of bioavailable fat but have substantially the same fat, cholesterol and caloric content as a like food without α-cyclodextrin. The invention also relates to methods for reducing the bioavailability of fats in fat containing food products without reducing caloric intake as determined by bomb calorimetry and to methods for increasing high density lipoproteins in a subject and reducing or controlling weight by administering the food products of this invention.12-06-2012
20090176737Composition for Soft Contact Lens and Adsorption Suppressing Method - Disclosed is a composition for soft contact lenses which enables to suppress adsorption of a basic chemical substance onto a soft contact lens. This composition for soft contact lenses comprises (A) a basic chemical substance selected from amines having a secondary amino group and/or a tertiary amino group and salts thereof, and (B) one or more substances selected from amino acids and salts thereof, acid mucopolysaccharides and salts thereof and cyclodextrin, while having a pH of 3.5 to 4.8. Also disclosed is a method for suppressing adsorption of the basic chemical substance onto a soft contact lens.07-09-2009
20110263528ANTIMICROBIAL COMPOSITIONS - This invention provides antimicrobial compositions containing methylglyoxal and material with methylglyoxal contained (such as manuka honey). The antimicrobial activity of methylglyoxal, or material with a methylglyoxal presence, is maintained and/or enhanced by mixing methylglyoxal or material with a methylglyoxal presence with cyclodextrin. Methods of preparing such compositions, including powder composition, and methods of using such compositions are also provided.10-27-2011
20100029585TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE - The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.02-04-2010
20110218173INCLUSION COMPLEXES OF PINOCEMBRIN WITH CYCLODEXTRIN OR ITS DERIVATIVES - Inclusion complexes of pinocembrin with cyclodextrin or its derivatives and their preparation are provided. The inclusion complexes can be used to make drugs.09-08-2011
20090023683COMPLEXES COMPRISING ZOLEDRONIC ACID AND CYCLODEXTRINS - The present invention relates to stable compositions comprising zoledronic acid, wherein zoledronic acid is complexed with a cyclodextrin, such as hydroxypropyl-β-cyclodextrin. The invention further relates to processes for making the compositions.01-22-2009
20100087392COMPLEXES OF IBUPROFEN, CYCLODEXTRINS AND TERNARY AGENTS AND THE USE THEREOF IN PHARMACEUTICS - The present invention relates to pharmaceutical compositions comprising ibuprofen in the form of an ibuprofen/cyclodextrin/lysine complex having improved pharmacokinetic properties compared with ibuprofen alone, such as a shortened Tmax and an increased Cmax.04-08-2010
20110152216ANAESTHETIC COMPOSITION - A stable anaesthetic composition is described which is particularly suitable for use in cats and dogs. The composition comprises an aqueous solution of an anaesthetically effective amount of a water soluble cyclodextrin or a cyclodextrin derivative complex of alfaxalone and a buffer, excluding phosphate buffer pH 7.0, 0.1M mixed as defined in the British Pharmacopoeia 1998, such that the pH of the solution is from 6.0-8.0.06-23-2011
20100056475CYCLODEXTRIN CONJUGATES - It has been discovered that the uptake of anionic charged species into cells can be enhanced by noncovalently associating such species with specifically modified forms of cyclodextrin. The invention modified forms of cyclodextrin form well defined stoichiometric complexes with anionic charged molecules. This discovery enables one to produce various compositions containing anionic charged molecules and facilitates methods for enhancing the cellular uptake of double-stranded or hairpin nucleic acid.03-04-2010
20100305063Water-Soluble Iron Carbohydrate Derivative Complexes, The Preparation Thereof, And Medicaments Comprising Them - Water-soluble iron-carbohydrate derivative complex obtainable from an aqueous iron(III) salt solution and an aqueous solution of the product of the oxidation and subsequent derivatisation of one or more maltodextrins with an aqueous hypochlorite solution at an alkaline pH value, wherein when one maltodextrin is used its dextrose equivalent is from 5 to 20 and when a mixture of a plurality of maltodextrins is used the dextrose equivalent of the mixture is from 5 to 20 and the dextrose equivalent of each individual maltodextrin in the mixture is from 2 to 40, and the subsequent derivatisation is carried out with a suitable reagent, process for the preparation thereof, and medicament for the treatment and prophylaxis of iron deficiency states.12-02-2010
20110009362SOLUBILITY-ENHANCED FORMS OF APREPITANT AND PHARMACEUTICAL COMPOSITIONS THEREOF - Solubility-enhanced forms of aprepitant and processes for preparing such forms. The invention also provides solubility-enhanced forms of aprepitant that also possess stability against solid state conversions. Certain solubility-enhanced forms of aprepitant comprise a cyclodextrin or any of its derivatives. Other solubility-enhanced forms of aprepitant comprise fine particle preparations of aprepitant. The invention further provides non-nanoparticulate pharmaceutical formulations prepared using solubility-enhanced forms of aprepitant. The invention also provides taste-masked and orally disintegrating pharmaceutical formulations comprising aprepitant. Further, pharmaceutical formulations comprising solubilityenhanced forms of aprepitant and processes of preparation of such formulations, as well as methods of using them are provided.01-13-2011
20080234225Method of treatment - A method and composition for preventing the formation of lesions in a patient having a site of inflammation by the use of a cromolyn compound. The cromolyn compound is used with a composition containing penetrating aids.09-25-2008
20120004195CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY - Methods and compositions relating to CDP-proteasome inhibitor conjugates are described herein.01-05-2012
20090143332Cyclodextrin Cyanohydrins - The present invention relates to a compound having a cyclodextrin skeleton wherein a hydrogen atom at the C-6 position in at least one of the sugar moieties has been substituted with a cyano group thereby forming a cyanohydrin-type group. The compounds are found to be excellent catalysts, e.g. for the hydrolysis of aryl glycosides. Accordingly, the compounds of the invention are useful as medicaments, in particular for the treatment of poisoning and drug abuse. The compounds, optionally immobilized to a solid phase material, are useful to reduce the content of harmful substances, e.g. metabolites of fungi, insects, etc., from compositions such as foodstuff.06-04-2009
20120058971CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY - Methods and compositions relating to CDP-taxane conjugates are described herein.03-08-2012
20120115810SURGICAL COMPOSITIONS FOR REDUCING THE INCIDENCE OF ADHESIONS - A method of preventing or reducing the incidence of post-operative adhesions in or associated with a body cavity, which comprises introducing into the body cavity a composition containing an aqueous solution or suspension or gel formulation containing the polysaccharide dextrin.05-10-2012
20120283214CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY - The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.11-08-2012
20100093664COMPOSITIONS USEFUL FOR REDUCING NEPHROTOXICITY AND METHODS OF USE THEREOF - The present invention provides compositions and methods to reduce renal damage caused by nephrotoxic drugs. The invention provides compositions comprising an anionically substituted cyclodextrin, a nephrotoxic drug and a pharmaceutically acceptable carrier, where the cyclodextrin is present in an amount effective for substantially inhibiting the nephrotoxic effect of the drug.04-15-2010
20100093663Sulfoalkyl Ether Cyclodextrin Compositions - SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.04-15-2010
20120316134ANAESTHETIC COMPOSITION - A stable anaesthetic composition is described which is particularly suitable for use in cats and dogs. The composition comprises an aqueous solution of an anaesthetically effective amount of water soluble cyclodextrin or a cyclodextrin derivative complex of alfaxalone and a bugger, excluding phosphate buffer pH 7.0, 0.1 M mixed as defined in the British Pharmadopoeia 1998, such that the pH of the solution is from 6.0-8.0.12-13-2012
20120316133AQUEOUS IRON CARBOHYDRATE COMPLEXES, THEIR PRODUCTION AND MEDICAMENTS CONTAINING THEM - A water soluble iron carbohydrate complex obtainable from an aqueous solution of iron(III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, a process for its production and a medicament for the treatment and prophylaxis of iron deficiency conditions.12-13-2012
20100069327NUTRITIONAL PRODUCTS COMPRISING SACCHARIDE OLIGOMERS - Indigestible oligosaccharides having a molecular weight of 450 Da to 3700 Da are used for the improvement of insulin resistance, the prevention of post-prandial glycaemic dip, and/or the decrease of the post-prandial glucose response of a meal, which is consumed within 72 hours after the consumption of the first product. The oligo-saccharides are especially galacto-oligosaccharides, and are advantageously administered a few hours prior to having the meal.03-18-2010
20100204178NOVEL PARENTERAL CARBAMAZEPINE FORMULATION - The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration.08-12-2010
20120214761PRE-MIXED, READY-TO-USE IV BOLUS NICARDIPINE COMPOSITIONS AND METHODS OF USE - Provided herein are ready-to-use premixed bolus injection pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.08-23-2012
20100048509Pharmaceutical Composition Comprising Perindopril - The present invention provides a stable pharmaceutical composition comprising an inclusion complex of perindopril, a microcrystalline cellulose having a low moisture content and/or a silicified microcrystalline cellulose having a low moisture content, and optionally other pharmaceutically acceptable excipients.02-25-2010
20120178711CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY - The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.07-12-2012
20120083467DEODORANT COMPOSITIONS - A deodorant composition contains β-cyclodextrin, a fixative, a preservative, and a solvent.04-05-2012
20090036406Injection - In the case of storing and supplying an injection containing a 2-[(2-pyridyl)methylsulfinyl]benzimidazole type compound in a plastic container in addition to a glass container, an injection having been improved in stability and solubility and showing excellent qualities without forming any insoluble foreign matters or insoluble microparticles can be obtained by using cyclodextrin or its derivative together.02-05-2009
20110237541TRANSDERMALLY ADMINISTERED ALISKIREN - Dosage form of aliskiren, comprising a device for transdermal administration of aliskiren and aliskiren (including salts, prodrugs and metabolites thereof), optionally together with pharmaceutically acceptable carrier(s) to a human being or an animal in order to achieve a desired therapeutic effect. Use of a compound comprising aliskiren, optionally encompassing salts, prodrugs and metabolites thereof, and optionally together with pharmaceutically acceptable carrier(s), for the manufacture of a composition to be administered transdermally for achieving a desired therapeutic effect. Method for achieving a desired therapeutic effect by transdermal administration of a compound comprising aliskiren, optionally encompassing salts, prodrugs and metabolites thereof, and optionally together with pharmaceutically acceptable carrier(s).09-29-2011
20100240607Dextrin-containing composition for preventing surgical adhesions - A method of preventing or reducing the incidence of post-operative adhesions in or associated with a body cavity, which comprises introducing into the body cavity a composition containing an aqueous solution or suspension or gel formulation containing the polysaccharide dextrin.09-23-2010
20100234321OILY COSMETIC AND COSMETIC PRODUCT - A composition is prepared to comprise (a) 50 to 99% by weight of an oily phase that is a liquid at 25° C., (b) 1 to 7% by weight of dextrin (palmitate/2-ethylhexanoate), and (c) 0.001 to 10% by weight of a coloring material and/or pearlescent agent other than a laminated film powder are contained, followed by making the viscosity thereof at 30° C. when measured with a BL viscometer to be 3,000 to 20,000 mPa·s. In addition, (d) silicic acid anhydride and/or hydrophobized silicic acid anhydride is added thereto.09-16-2010
20120277184BLOCKERS OF PORE-FORMING VIRULENCE FACTORS AND THEIR USE AS ANTI-INFECTIVES - The invention provides methods for treating, delaying, and preventing pathological conditions caused by pore-forming toxins such as anthrax toxin, α-hemolysin toxin, and ε-toxin using a class of low molecular weight compounds that block the pore formed by these toxins. Specific compounds useful for treating, preventing, or delaying a disease condition caused by 11-01-2012
20120289479Materials and Methods Related to Sodium/Potassium Adenosine Triphosphate and Cholesterol - This invention is based in part on the elucidation of new structural conformations and functions of the sodium/potassium adenosine triphosphate synthase (Na/K ATPase), and especially elucidation of new binding sites and interactions. The present invention provides practical applications of several surprising structural and functional relationships between Na/K ATPase and compounds which interact with Na/K ATPase. Disclosure of these structures and relationships provides insight and practical solutions to chemically affecting not only the Na/K ATPase interactions, but also regulators known to be upstream and downstream.11-15-2012
20120289480CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY - The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.11-15-2012
20100130444COMPLEXES OF PROSTAGLANDIN DERIVATIVES AND MONOSUBSTITUTED, CHARGED BETA-CYCLODEXTRINS - The present invention relates to water-soluble, non-covalent complexes of a group of prostaglandin derivatives including latanoprost and monosubstituted, charged β-cyclodextrins, as well as uses of these complexes in therapeutic compositions that are administered topically for treating intraocular hypertension and glaucoma.05-27-2010
20100173869TREATMENT OF SURFACTANTS - The invention relates to a method for treatment of a surfactant, in particular a pulmonary surfactant. The method is further established in that the surfactant is treated with a lipid sequestrating or cholesterol sequestrating surfactant treatment agent, in which given, in particular neutral lipids or cholesterol are selectively sequestrated by means of the surfactant treatment agent, such that the effect of the lipids and/or the effect of the cholesterol on the surfactant is reduced or reversed.07-08-2010
20110160159TREATMENT OF CANCER - Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.06-30-2011
20130172291RETINAL CYCLODEXTRIN ACETALS AND HEMIACETALS FOR TREATING SKIN COMPLEXION DISORDER - The present invention discloses certain polyene cyclodextrin acetals and hemiacetals that are effective in providing skin clarification, which is useful for the treatment of acne, and skin disfigurements and skin darkening resulting from acne; skin darkening from cancer, diabetes, radiation treatments, chemotherapy, and sun-burn; mitochondrial and DNA dysfunction; age spots; loss of cellular antioxidants; skin changes associated with aging including collagen loss, loss of skin pliability, loss of skin suppleness, skin wrinkles and fine lines, oxidation, damage from radiation, damage from free radicals, and damage from UV; dry skin; xerosis; ichthyosis; dandruff; brownish spots; keratoses; melasma; lentigines; liver spots; skin pigmentation including pigmented spots, dark circles under the eyes, darkened skin, and blemishes; oily skin; warts; eczema; pruritic skin; psoriasis; inflammatory dermatoses; topical inflammation; disturbed keratinization; scalp dryness, and combinations thereof.07-04-2013
20080221065ORGANIC COMPOUNDS - Pharmaceutical formulations comprising an epothilone in the form of an infusion concentrate or a lyophilised composition, and methods of administration of an epothilone in suitable form for parenteral administration.09-11-2008
20090005343B-CYCLODEXTRIN DERIVATIVES AND THEIR USE AGAINST ANTHRAX LETHAL TOXIN - The invention provides low molecular weight compounds that block the pore formed by protective antigen and inhibit anthrax toxin action. Structures of the compounds are derivatives of β-cyclodextrin. Per-substituted alkylamino derivatives displayed inhibitory activity, and they were protective against anthrax lethal toxin action at low micromolar concentrations. Also, the addition of one of the alkylamino derivatives to the bilayer lipid membrane with multiple PA channels caused a significant decrease in membrane conductance. Thus, the invention also provides methods for protection against anthrax toxicity.01-01-2009
20080214496Use Of Iron(III) Complex Compounds - The present invention relates to novel therapeutic uses of iron(III) complex compounds with carbohydrates or derivatives thereof, in the preparation of a medicament for improving immune defence and/or brain performance.09-04-2008
20130131013CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY - The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.05-23-2013
20110224168FAT-BINDING COMPOSITIONS - A fat-binding composition contains an inclusion complex with a host molecule and a guest molecule. The guest molecule includes one or more amino acids, vitamins, flavorants or related compounds, rutin, betanin, derivatives thereof, and mixtures thereof. The fat-binding composition may be in the form of a tablet or powder, for example, and may be incorporated into a food or beverage product. If in the form of a powder or tablet, the composition may optionally contain a carbonation-forming component and may be dissolved in carbonated or non-carbonated water. The fat-binding composition may also be employed in a method for binding fat ingested by an animal which includes having the animal ingest the composition, or a food or beverage product containing the same.09-15-2011
20110275594Oral dosage form - A pharmaceutical or nutraceutical tablet for oral administration comprising at least two fatty acids or derivatives thereof and cyclodextrin.11-10-2011
20110237540CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY - Methods and compositions relating to CDP-taxane conjugates are described herein.09-29-2011
20130137657QUATERNISED AMMONIUM CYCLODEXTRIN COMPOUNDS - Use of a compound of formula (I):05-30-2013
20130157975AGENT FOR SUPPRESSING ELEVATION OF BLOOD ALCOHOL CONCENTRATION - An object of the present invention is to provide an agent for suppressing elevation of blood alcohol concentration and a method for suppressing elevation of blood alcohol concentration, the agent and the method enabling prevention of an intoxication state upon drinking and further prevention of hepatic dysfunctions due to drinking such as fatty liver. Provided are an agent for suppressing elevation of blood alcohol concentration, comprising a dextrin as an active ingredient, and a method for suppressing elevation of blood alcohol concentration, comprising, when alcohol is ingested, ingesting 0.5 parts by mass or more of a digestible dextrin and/or an indigestible dextrin relative to 1 part by mass of the ingested alcohol.06-20-2013
20130184236COMPOUND HAVING DETRUSOR MUSCLE-CONTRACTING ACTIVITY AND URETHRAL SPHINCTER MUSCLE-RELAXING ACTIVITY - Since a compound represented by formula (I) wherein all of the symbols are the same as defined in the specification, a salt thereof, a solvate thereof, a prodrug thereof, a mixture with a diastereomer thereof in an arbitrary ratio, or a cyclodextrin clathrate thereof have a contracting activity of bladder detrusor and a relaxing activity of urethral sphincter, they can ameliorate bladder contraction dysfunction and/or urethral relaxation dysfunction, and for example, are effective for underactive bladder. Additionally, the compound of the present invention has little risk of side effects on the urinary system, the circulatory system and the digestive system, and exhibits excellent pharmacokinetics, such as oral absorbability etc. Therefore, the compound of the present invention is useful as a superior agent for preventing, treating and/or ameliorating underactive bladder.07-18-2013
20080318898INCLUSION COMPLEXES OF BUTYLPHTHALIDE WITH CYCLODEXTRIN OR ITS DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THE USE THEREOF - The present invention relates to the inclusion complexes of butylphthalide, which is D, L-mixed or levorotatory, with cyclodextrin or cyclodextrin derivatives, to a process for their preparation and the use thereof. In the invention, the butylphthalide is complexed with cyclodextrin or cyclodextrin derivatives, preferably with hydroxypropyl-β-cyclodextrin in order to increase the water-solubility of butylphthalide, develop clinical solid or liquid formulations and improve the therapeutic effect of butylphthalide. The inclusion complex, in which the molar ratio of butylphthalide to cyclodextrin or cyclodextrin derivatives is in the range of 1:1-10, can be used to prepare infusion, injection, injectable powder, liquids for oral administration, syrup, tablets, granules, dispersible tablets and others.12-25-2008
20110312914CARBON MONOXIDE REMOVAL AGENT - The present invention provides a carbon monoxide removal agent that can be easily administered to a patient by injection or orally. The carbon monoxide removal agent of the present invention contains, as an active ingredient, an inclusion complex in which a cyclodextrin dimer represented by chemical formula (1) below includes a water-soluble metalloporphyrin. (In the formula, m represents either of number 1 or 2 and n represents any of number 1, 2, or 3.)12-22-2011
20100081631METHODS AND COMPOSITIONS FOR TREATING GASTROINTENSTIAL DISORDERS - Methods are provided directed to administering a therapeutically effective amount of a prostaglandin EP04-01-2010
20120028918PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME - The present invention relates to pharmaceutical compositions that include about 10 mg pazopanib/mL of the composition and about 2 to about 13% w/w of a modified cyclodextrin as well as methods of making the same are described.02-02-2012
20130196945CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY - The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.08-01-2013
20130196948POLYMERS FOR BIOMATERIALS AND THERAPEUTICS - Described herein are inventive compositions and methods relating to polymer conjugates and, in particular, to polymer conjugates having pendant side groups comprising ring moieties. In one aspect, embodiments are generally related to compositions that mimic naturally-occurring polyphenol compounds. The compositions comprise, in some embodiments, a polymer backbone having a plurality of hydroxyaromatic pendant side groups or derivatives thereof. For example, in some cases, a pendant side group may be a phenol or a substituted derivative thereof. In some cases, the pendant side group may be an oxidized hydroxyaromatic group, such as a quinone. In some embodiments, self-assembled structures comprising one or more of the polymer conjugates are provided. For example, the polymer conjugates may be combined with a complexing agent to form a particle. In some cases, a polymer conjugate may form a hydrogel. In some embodiments, the self-assembled structures may contain an agent, such as a pharmaceutically active agent. Also provided are methods and kits for forming the compositions, methods of using the compositions, and the like.08-01-2013
20130196947USE OF CYCLODEXTRIN FOR TREATMENT AND PREVENTION OF BRONCHIAL INFLAMMATORY DISEASES - The invention provides the use of a cyclodextrin compound for the manufacturing of a medicament for the treatment or prevention of bronchial inflammatory diseases, particularly for asthma and chronic obstructive pulmonary disease (COPD).08-01-2013
20130196946CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY - Methods and compositions relating to CDP-taxane conjugates are described herein.08-01-2013
20130203700CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY - The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.08-08-2013
20120094954COMPOSITIONS COMPRISING AT LEAST ONE COMPLEX COMPOSED OF A DERIVATIVE OF NAPHTHOIC ACID AND OF AT LEAST ONE CYCLODEXTRIN AND USES THEREOF - A composition is described for topical application comprising, in a physiologically acceptable medium, at least one complex composed of a naphthoic acid derivative of formula (I), salts and esters thereof:04-19-2012

Patent applications in class Dextrin or derivative